本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Trevi Therapeutics Inc.

6.86
+0.02000.29%
盘后6.990.1300+1.90%18:14 EDT
成交量:226.23万
成交额:1,584.73万
市值:8.17亿
市盈率:-15.43
高:7.19
开:6.92
低:6.80
收:6.84
数据加载中...
2024/03/20

重要事件披露

Form 8-K - Current report
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/12

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/11/10

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/10

重要事件披露

Form 8-K - Current report
2023/09/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/15

SEC问询函

Form CORRESP - Correspondence
2023/08/11

重要事件披露

Form 8-K - Current report
2023/08/10

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/06/29

重要事件披露

Form 8-K - Current report
2023/06/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/11

重要事件披露

Form 8-K - Current report
2023/05/11

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/05/11

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/04/14

重要事件披露

8-K - Current report
2023/04/11

关联方拟减持公告

144 - Report of proposed sale of securities
2023/03/16

重要事件披露

8-K - Current report
2023/03/16

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]